Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?

Cardiovasc Res · 2022 · PMC9648826 · PMID 34849601

Europe PMC DOI

hedged sentence

0.0400

closest p · 0.8× alpha

0.0400

boldest claim

The sentences

nominally significantP = 0.04actually significant

While evacetrapib did not demonstrate overall major adverse CVD events (MACE) reduction at 26 months, there were no significant safety signals, and a nominally significant ( P = 0.04) reduction in total mortality was observed. 6.4 Anacetrapib The most recent CETP inhibitor tested in clinical trials was anacetrapib.

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.